ABOS · Acumen Pharmaceuticals, Inc.

Summary

Acumen Pharmaceuticals reported financial results for the year ended December 31, 2025, with net loss of $121.3 million, R&D expenses of $104.9 million, and cash, cash equivalents and marketable securities of $116.9 million expected to fund operations into early 2027. The company provided business highlights including ALTITUDE-AD Phase 2 topline results expected late 2026, EBD program IND targeted mid-2027, and a $35.75 million private placement completed March 16, 2026.

Key takeaways

• Corporate presentation updated and posted to website March 26, 2026, reflecting cash balance and private placement.